ArticleMethods in molecular biology (Clifton, N.J.)2014
Serum profiling using protein microarrays to identify disease related antigens.
Article in Methods in molecular biology (Clifton, N.J.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1.Scientific reports · 2016Trial
- Pro-MAP: a robust pipeline for the pre-processing of single channel protein microarray data.BMC bioinformatics · 2022Article
- Article
- Heterosubtypic, cross-reactive immunity to human Cytomegalovirus glycoprotein B.Clinical and experimental immunology · 2022Article
- Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq.bioRxiv : the preprint server for biology · 2022Article
- Glass Slide-Printed Protein Arrays as a Platform to Discover Serodiagnostic Antigens Against Bacterial Infections.Methods in molecular biology (Clifton, N.J.) · 2021Article
- PAWER: protein array web exploreR.BMC bioinformatics · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Disease related antigens are of great importance in the clinic. They are used as markers to screen patients for various forms of cancer, to monitor response to therapy, or to serve as therapeutic targets (Chapman et al., Ann Oncol 18(5):868-873, 2007; Soussi et al., Cancer Res 60:1777-1788, 2000; Anderson and LaBaer, J Proteome Res 4:1123-1133, 2005; Levenson, Biochim Biophy Acta 1770:847-856, 2007). In cancer endogenous levels of protein expression may be disrupted or proteins may be expressed in an aberrant fashion resulting in an immune response that bypasses self tolerance (Soussi et al., Cancer Res 60:1777-1788, 2000; Disis et al., J Clin Oncol 15(11):3363-3367, 1997; Molina et al., Breast Cancer Res Treat 51:109-119, 1998). Protein microarrays, which represent a large fraction of the human proteome, have been used to identify antigens in multiple diseases including cancer (Anderson and LaBaer, J Proteome Res 4:1123-1133, 2005; Disis et al., J Clin Oncol 15(11):3363-3367, 1997; Hudson et al., Proc Natl Acad Sci U S A 104(44):17494-17499, 2007; Beyer et al., J Neuroimmunol 242:26-32, 2012). Typically, arrays are probed with immunoglobulin (Ig) samples from patients as well as healthy controls, then compared to determine which antigens (Ag's) are more reactive within the patient group (Hudson et al., Proc Natl Acad Sci U S A 104(44):17494-17499).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.